Literature DB >> 31025748

A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus.

V P Werth1,2, J T Merrill3.   

Abstract

Entities:  

Year:  2019        PMID： 31025748      PMCID： PMC6768407          DOI： 10.1111/bjd.17344

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  12 in total

1.  The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score.

Authors:  I Braunstein; R Klein; J Okawa; V P Werth
Journal:  Br J Dermatol       Date:  2012-05       Impact factor: 9.302

2.  Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus.

Authors:  Rachel Klein; Siamak Moghadam-Kia; Jonathan LoMonico; Joyce Okawa; Chris Coley; Lynne Taylor; Andrea B Troxel; Victoria P Werth
Journal:  Arch Dermatol       Date:  2011-02

3.  Upcoming therapeutic targets in cutaneous lupus erythematous.

Authors:  Anna Sophie Klaeschen; Joerg Wenzel
Journal:  Expert Rev Clin Pharmacol       Date:  2016-02-29       Impact factor: 5.045

4.  Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

Authors:  Daniel J Wallace; Richard A Furie; Yoshiya Tanaka; Kenneth C Kalunian; Marta Mosca; Michelle A Petri; Thomas Dörner; Mario H Cardiel; Ian N Bruce; Elisa Gomez; Tara Carmack; Amy M DeLozier; Jonathan M Janes; Matthew D Linnik; Stephanie de Bono; Maria E Silk; Robert W Hoffman
Journal:  Lancet       Date:  2018-07-21       Impact factor: 79.321

5.  Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations.

Authors:  Josef Symon S Concha; Aikaterini Patsatsi; Ann Marshak-Rothstein; Ming-Lin Liu; Animesh A Sinha; Lela A Lee; Joseph F Merola; Ali Jabbari; Johann E Gudjonsson; François Chasset; Paul Jarrett; Benjamin Chong; Lisa Arkin; Anthony P Fernandez; Marzia Caproni; Steven A Greenberg; Hee Joo Kim; David R Pearson; Alisa Femia; Ruth Ann Vleugels; David Fiorentino; Manabu Fujimoto; Joerg Wenzel; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2018-09-19       Impact factor: 8.551

6.  Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.

Authors:  Ronald F van Vollenhoven; Bevra H Hahn; George C Tsokos; Carrie L Wagner; Peter Lipsky; Zahi Touma; Victoria P Werth; Robert M Gordon; Bei Zhou; Benjamin Hsu; Marc Chevrier; Manon Triebel; Jarrat L Jordan; Shawn Rose
Journal:  Lancet       Date:  2018-09-21       Impact factor: 79.321

7.  Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.

Authors:  Majid Zeidi; Hee Joo Kim; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2018-09-15       Impact factor: 8.551

8.  Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.

Authors:  Richard Furie; Munther Khamashta; Joan T Merrill; Victoria P Werth; Kenneth Kalunian; Philip Brohawn; Gabor G Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

Review 9.  Lupus community panel proposals for optimising clinical trials: 2018.

Authors:  Joan T Merrill; Susan Manzi; Cynthia Aranow; Anca Askanase; Ian Bruce; Eliza Chakravarty; Ben Chong; Karen Costenbader; Maria Dall'Era; Ellen Ginzler; Leslie Hanrahan; Ken Kalunian; Joseph Merola; Sandra Raymond; Brad Rovin; Amit Saxena; Victoria P Werth
Journal:  Lupus Sci Med       Date:  2018-03-23

10.  Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.

Authors:  Munther Khamashta; Joan T Merrill; Victoria P Werth; Richard Furie; Kenneth Kalunian; Gabor G Illei; Jorn Drappa; Liangwei Wang; Warren Greth
Journal:  Ann Rheum Dis       Date:  2016-03-23       Impact factor: 19.103
View more
  3 in total

Review 1.  Emerging Therapies in Cutaneous Lupus Erythematosus.

Authors:  Grant Sprow; Joshua Dan; Joseph F Merola; Victoria P Werth
Journal:  Front Med (Lausanne)       Date:  2022-07-11

Review 2.  Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus.

Authors:  Minhui Wang; Ziqian Wang; Shangzhu Zhang; Yang Wu; Li Zhang; Jiuliang Zhao; Qian Wang; Xinping Tian; Mengtao Li; Xiaofeng Zeng
Journal:  J Clin Med       Date:  2022-08-24       Impact factor: 4.964

Review 3.  Anti-Cytokine Autoantibodies in Systemic Lupus Erythematosus.

Authors:  Hwee Siew Howe; Bernard Pui Lam Leung
Journal:  Cells       Date:  2019-12-27       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.